小容量注射剂市场－全球产业规模、份额、趋势、机会及预测（依剂型、类型、包装、适应症、地区及竞争格局划分，2021-2031年）

全球小容量注射剂市场预计将从 2025 年的 2,065.5 亿美元成长到 2031 年的 3,108.5 亿美元，年复合成长率为 7.05%。

小容量注射剂是指包装在100毫升或以下容器的无菌注射液，是麻醉剂、诊断试剂和药品给药的必需品。此市场成长的主要驱动因素是需要即时治疗的慢性疾病发病率不断上升，以及重症监护环境中对便捷注​​射剂型的需求日益增长，从而确保了全球医疗保健系统将继续依赖这些药物製剂来支持患者的快速稳定和治疗。

然而，该行业面临着与生产复杂性和维持严格的无菌条件相关的重大障碍，这些因素将严重损害供应链的可靠性。近期有关生产一致性的产业数据凸显了这项营运挑战。据美国卫生系统药剂师协会 (ASHP) 称，2024 年已确定的新药短缺中，约 48% 将是注射剂短缺。这项统计数据表明，製造商在满足全球对这些关键无菌产品的高需求的同时，还要遵守严格的品质标准，这仍然是一个难题。

市场驱动因素

慢性病和文明病的日益增加是全球小容量注射剂市场的主要驱动力，也因此对治疗管理所需的稳定无菌注射剂供应产生了根本性的需求。肿瘤和糖尿病等疾病需要经常透过管瓶、安瓿或预填充式注射器注射强效药物，以有效控制病情进展。这种需求在肿瘤领域尤其突出，因为精准的化疗剂量依赖小容量製剂以确保安全性和有效性。值得注意的是，根据美国癌症协会于2024年1月发布的《2024年癌症事实与数据》，预计美国新增癌症病例数将首次超过200万例，这将进一步增加临床对注射剂的需求。

同时，生物製药和生物相似药产业的快速扩张正在重塑市场格局。这些复杂的製剂通常需要肠外给药以维持生物利用度。标靶生物製药疗法的兴起推动了製剂稳定性的创新，并促使人们倾向于采用能够简化给药的密封系统。这一趋势也体现在监管结果中。美国食品药物管理局（FDA）药物评估与研究中心在其2024年1月发布的《2023年新药核准情况报告》中指出，共有55种新疗法核准，这标誌着注射剂领域的创新再次兴起。为了满足对无菌生产日益增长的需求，各公司正积极扩大其业务规模。例如，诺和诺德公司于2024年6月宣布投资41亿美元，用于扩建位于北卡罗来纳州的表面处理工程生产基地。

市场挑战

严格的无菌操作和无菌注射剂生产固有的复杂性，对全球小容量注射剂市场构成了重大瓶颈。与口服药物不同，小容量注射剂通常需要无菌处理，这是一个高度复杂的过程，要求从配製到包装的整个过程中都必须保持产品无菌，且无需最终灭菌。由于这种复杂性，即使是设施环境条件、设备校准或水质方面的微小偏差，都可能导致即时且长时间的停产，以便调查潜在的污染，从而扰乱生产计划，并使供应商无法持续满足全球需求。

生产线的这种不稳定性得到了近期行业统计数据的支持，这些数据凸显了此类产品类型的脆弱性。 2024年，美国药典（USP）发布的一份供应链风险分析报告显示，新发现的药品短缺中，53%是非专利无菌注射。这一数字表明，维持无菌状态所固有的操作挑战与产品供应直接相关。当製造商因品质保证方面的高门槛而无法持续生产这些必需产品时，市场将面临实际的限制，无法满足现有需求，而这与患者的需求无关。

市场趋势

即用型 (RTU) 和即用型 (RTA) 药品的普及正在从根本上改变供应链，将灭菌的负担从製药公司转移到包装供应商。透过使用预先清洁和预灭菌的管瓶、药筒和注射器，製药公司可以省去复杂的内部无菌处理步骤，从而加快产品上市速度，并减少在清洁和热力消毒设备上的资本支出。这种营运模式的转变对于高价值生技药品成长了 17%，达到 1.004 亿欧元。

同时，在严格的环境法规和企业脱碳努力的推动下，市场正策略性地转向永续和环保的包装材料。为了减少一次性注射对环境的影响，製造商优先考虑采用低碳生产方法和循环经济原则来生产玻璃和聚合物容器。这项努力也延伸至节能的生产工艺，这些工艺在不影响无菌保证的前提下，显着减少了范围 1 和范围 2 的排放。例如，萧特製药在其于 2024 年 1 月发布的《2022/2023 永续发展报告》中指出，其范围 1 和范围 2 的二氧化碳排放减少了 60%，并实现了 100% 使用绿色电力，这表明该行业在实现全球气候中和目标方面取得了进展。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球小剂量注射剂市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依形态（液体、干燥剂）
  • 依类型（单剂量、多剂量）
  • 依包装形式（安瓿瓶、管瓶、预填充式注射器、药筒、瓶子等）
  • 依适应症（疼痛管理、癌症治疗、营养不良、胃肠道疾病/腹泻、糖尿病、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美小容量注射剂市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲小容量注射剂市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区小剂量注射剂市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲小容量注射剂市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲小容量注射剂市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球小容量注射剂市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• BML Parenteral Drugs
• Rusoma Laboratories Pvt Ltd
• B Braun Melsungen AG
• Fresenius Kabi AG
• Baxter International Inc.
• Sichuan Kelun Pharmaceutical Co Ltd

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Small Volume Parenteral Market is projected to expand from USD 206.55 Billion in 2025 to USD 310.85 Billion by 2031, reflecting a compound annual growth rate of 7.05%. Small volume parenterals are characterized as sterile injectable products packaged in containers of 100 milliliters or less, which are essential for administering anesthetics, diagnostic agents, and medications. The growth of this market is primarily driven by the increasing incidence of chronic conditions demanding immediate therapeutic action and the rising requirement for convenient injectable dosage forms within critical care environments, ensuring a continued reliance on these pharmaceutical preparations to support rapid patient stabilization and treatment across global healthcare systems.

However, the industry faces substantial obstacles related to manufacturing intricacies and the strict maintenance of sterility, factors that can severely compromise the reliability of the supply chain. This operational challenge is highlighted by recent industry data regarding production consistency; according to the American Society of Health-System Pharmacists, approximately 48% of new drug shortages identified in 2024 were injectable medications. This statistic emphasizes the ongoing difficulty manufacturers encounter in aligning production output with the high global demand for these critical sterile products while simultaneously adhering to rigorous quality standards.

Market Driver

The escalating prevalence of chronic and lifestyle-associated diseases acts as a major catalyst for the Global Small Volume Parenteral Market, creating a fundamental need for a steady supply of sterile injectables for therapeutic management. Conditions such as oncology and diabetes mandate the frequent administration of potent pharmaceutical agents via vials, ampoules, or pre-filled syringes to effectively control disease progression. This demand is especially acute in oncology, where precise chemotherapy dosing relies on small volume formats for safety and efficacy; notably, the American Cancer Society's 'Cancer Facts & Figures 2024' reported in January 2024 that new cancer cases in the United States were projected to exceed 2 million for the first time, signaling an intensifying need for parenteral solutions in clinical settings.

Simultaneously, the market is being reshaped by the rapid expansion of the biologics and biosimilars sector, as these complex formulations generally require parenteral delivery to preserve bioavailability. The transition toward targeted biologic therapies has spurred innovations in formulation stability, favoring containment systems that simplify administration. This trend is reflected in regulatory achievements; the FDA Center for Drug Evaluation and Research noted in its 'New Drug Therapy Approvals 2023' report, released in January 2024, that 55 novel therapeutics were approved, indicating a resurgence in innovation focused on injectables. To accommodate this surging requirement for sterile manufacturing, companies are aggressively scaling operations, such as Novo Nordisk's June 2024 announcement of a $4.1 billion investment to expand its fill and finish footprint in North Carolina.

Market Challenge

The rigorous maintenance of sterility assurance and the inherent complexity of manufacturing sterile injectables create a significant bottleneck for the Global Small Volume Parenteral Market. Unlike oral medications, small volume parenterals frequently require aseptic processing, a highly intricate method where the product must remain sterile throughout formulation and packaging without terminal sterilization. Because of this complexity, even minor deviations in facility environmental conditions, equipment calibration, or water quality can trigger immediate and lengthy production halts to investigate potential contamination, thereby disrupting schedules and preventing suppliers from consistently meeting global volume requirements.

This instability within the production pipeline is substantiated by recent industry statistics highlighting the vulnerability of this specific product category. In 2024, the U.S. Pharmacopeia released an analysis of supply chain risks revealing that 53% of all new drug shortages identified were generic sterile injectable medicines. This figure demonstrates that the specific operational difficulties associated with maintaining sterility directly correlate with product unavailability; when manufacturers are unable to reliably produce these essential units due to the high barrier of quality assurance, the market becomes physically constrained by an inability to fulfill existing demand, regardless of patient need.

Market Trends

The proliferation of Ready-to-Use (RTU) and Ready-to-Administer (RTA) formulations is fundamentally altering the supply chain by shifting the burden of sterilization from pharmaceutical companies to packaging suppliers. By utilizing pre-washed, pre-sterilized vials, cartridges, and syringes, drug manufacturers can bypass complex in-house aseptic processing steps, thereby accelerating time-to-market and reducing capital expenditure on washing and depyrogenation equipment. This operational shift is particularly critical for high-value biologics where containment integrity and speed are paramount, a trend evidenced by the financial performance of key packaging suppliers; according to the Stevanato Group's November 2024 report on third-quarter financial results, revenue from high-value solutions, including pre-sterilized platforms, rose by 17% to €100.4 million.

Concurrently, the market is undergoing a strategic transition toward sustainable and eco-friendly packaging materials, driven by stringent environmental regulations and corporate decarbonization mandates. Manufacturers are increasingly prioritizing low-carbon production methods and circular economy principles for glass and polymer containers to mitigate the environmental footprint of single-use parenterals. This commitment extends to energy-efficient manufacturing processes that drastically lower Scope 1 and Scope 2 emissions without compromising sterility assurance; for instance, Schott Pharma reported in its 'Sustainability Report 2022/2023' in January 2024 that the company achieved a 60% reduction in Scope 1 and Scope 2 CO2 emissions and transitioned to 100% green electricity, underscoring the sector's alignment with global climate neutrality goals.

Key Market Players

• BML Parenteral Drugs
• Rusoma Laboratories Pvt Ltd
• B Braun Melsungen AG
• Fresenius Kabi AG
• Baxter International Inc.
• Sichuan Kelun Pharmaceutical Co Ltd

Report Scope

In this report, the Global Small Volume Parenteral Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Small Volume Parenteral Market, By Form

• Liquid
• Dry

Small Volume Parenteral Market, By Type

• Single-dose
• Multiple-dose

Small Volume Parenteral Market, By Packaging

• Ampoules
• Vials
• Pre-filled Syringes
• Cartridges
• Bottles
• Others

Small Volume Parenteral Market, By Indication

• Pain Management
• Cancer Care
• Malnourishment
• Gastrointestinal Disorder/Diarrhea
• Diabetes
• Others

Small Volume Parenteral Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Small Volume Parenteral Market.

Available Customizations:

Global Small Volume Parenteral Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Small Volume Parenteral Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Form (Liquid, Dry)
  • 5.2.2. By Type (Single-dose, Multiple-dose)
  • 5.2.3. By Packaging (Ampoules, Vials, Pre-filled Syringes, Cartridges, Bottles, Others)
  • 5.2.4. By Indication (Pain Management, Cancer Care, Malnourishment, Gastrointestinal Disorder/Diarrhea, Diabetes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Small Volume Parenteral Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Form
  • 6.2.2. By Type
  • 6.2.3. By Packaging
  • 6.2.4. By Indication
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Small Volume Parenteral Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Form
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Packaging
      • 6.3.1.2.4. By Indication
  • 6.3.2. Canada Small Volume Parenteral Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Form
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Packaging
      • 6.3.2.2.4. By Indication
  • 6.3.3. Mexico Small Volume Parenteral Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Form
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Packaging
      • 6.3.3.2.4. By Indication

7. Europe Small Volume Parenteral Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Form
  • 7.2.2. By Type
  • 7.2.3. By Packaging
  • 7.2.4. By Indication
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Small Volume Parenteral Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Form
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Packaging
      • 7.3.1.2.4. By Indication
  • 7.3.2. France Small Volume Parenteral Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Form
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Packaging
      • 7.3.2.2.4. By Indication
  • 7.3.3. United Kingdom Small Volume Parenteral Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Form
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Packaging
      • 7.3.3.2.4. By Indication
  • 7.3.4. Italy Small Volume Parenteral Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Form
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Packaging
      • 7.3.4.2.4. By Indication
  • 7.3.5. Spain Small Volume Parenteral Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Form
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Packaging
      • 7.3.5.2.4. By Indication

8. Asia Pacific Small Volume Parenteral Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Form
  • 8.2.2. By Type
  • 8.2.3. By Packaging
  • 8.2.4. By Indication
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Small Volume Parenteral Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Form
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Packaging
      • 8.3.1.2.4. By Indication
  • 8.3.2. India Small Volume Parenteral Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Form
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Packaging
      • 8.3.2.2.4. By Indication
  • 8.3.3. Japan Small Volume Parenteral Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Form
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Packaging
      • 8.3.3.2.4. By Indication
  • 8.3.4. South Korea Small Volume Parenteral Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Form
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Packaging
      • 8.3.4.2.4. By Indication
  • 8.3.5. Australia Small Volume Parenteral Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Form
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Packaging
      • 8.3.5.2.4. By Indication

9. Middle East & Africa Small Volume Parenteral Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Form
  • 9.2.2. By Type
  • 9.2.3. By Packaging
  • 9.2.4. By Indication
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Small Volume Parenteral Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Form
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Packaging
      • 9.3.1.2.4. By Indication
  • 9.3.2. UAE Small Volume Parenteral Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Form
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Packaging
      • 9.3.2.2.4. By Indication
  • 9.3.3. South Africa Small Volume Parenteral Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Form
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Packaging
      • 9.3.3.2.4. By Indication

10. South America Small Volume Parenteral Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Form
  • 10.2.2. By Type
  • 10.2.3. By Packaging
  • 10.2.4. By Indication
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Small Volume Parenteral Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Form
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Packaging
      • 10.3.1.2.4. By Indication
  • 10.3.2. Colombia Small Volume Parenteral Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Form
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Packaging
      • 10.3.2.2.4. By Indication
  • 10.3.3. Argentina Small Volume Parenteral Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Form
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Packaging
      • 10.3.3.2.4. By Indication

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Small Volume Parenteral Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. BML Parenteral Drugs
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Rusoma Laboratories Pvt Ltd
• 15.3. B Braun Melsungen AG
• 15.4. Fresenius Kabi AG
• 15.5. Baxter International Inc.
• 15.6. Sichuan Kelun Pharmaceutical Co Ltd

16. Strategic Recommendations

17. About Us & Disclaimer